Robert A Hauser

Summary

Affiliation: University of South Florida
Country: USA

Publications

  1. doi request reprint IPX066: a novel carbidopa-levodopa extended-release formulation
    Robert A Hauser
    University of South Florida Parkinson s Disease and Movement Disorders Center, NPF Center of Excellence, Byrd Institute, 4001 E Fletcher Ave, 6th Floor, Tampa, FL 33613, USA
    Expert Rev Neurother 12:133-40. 2012
  2. ncbi request reprint Tozadenant (SYN115) in patients with Parkinson's disease who have motor fluctuations on levodopa: a phase 2b, double-blind, randomised trial
    Robert A Hauser
    University of South Florida Parkinson s Disease and Movement Disorders Center, National Parkinson Foundation Center of Excellence, Tampa, FL, USA Electronic address
    Lancet Neurol 13:767-76. 2014
  3. doi request reprint Extended-release carbidopa-levodopa (IPX066) compared with immediate-release carbidopa-levodopa in patients with Parkinson's disease and motor fluctuations: a phase 3 randomised, double-blind trial
    Robert A Hauser
    University of South Florida, Tampa, FL, USA
    Lancet Neurol 12:346-56. 2013
  4. doi request reprint AbobotulinumtoxinA (Dysport) dosing in cervical dystonia: an exploratory analysis of two large open-label extension studies
    Robert A Hauser
    Parkinson s Disease and Movement Disorders Center, NPF Center of Excellence, Byrd Institute, University of South Florida, 4001 E Fletcher Ave, 6th Floor, Tampa, FL 33613, USA
    J Neural Transm 120:299-307. 2013
  5. doi request reprint [123I]FP-CIT (DaTscan) SPECT brain imaging in patients with suspected parkinsonian syndromes
    Robert A Hauser
    Department of Neurology, Parkinson s Disease and Movement Disorders Center, University of South Florida, Tampa, FL 33606, USA
    J Neuroimaging 22:225-30. 2012
  6. doi request reprint The UPDRS-8: a brief clinical assessment scale for Parkinson's disease
    Robert A Hauser
    Departments of Neurology, Molecular Pharmacology and Physiology, University of South Florida, Tampa, FL, USA
    Int J Neurosci 122:333-7. 2012
  7. doi request reprint Levodopa response in early Parkinson's disease
    Robert A Hauser
    Department of Neurology, University of South Florida, Tampa, Florida 33606, USA
    Mov Disord 24:2328-36. 2009
  8. doi request reprint Levodopa: past, present, and future
    Robert A Hauser
    Departments of Neurology, Molecular Pharmacology, and Physiology, University of South Florida, Tampa, FL 33606, USA
    Eur Neurol 62:1-8. 2009
  9. doi request reprint Randomized, double-blind, pilot evaluation of intravenous glutathione in Parkinson's disease
    Robert A Hauser
    Department of Neurology, University of South Florida, Tampa, Florida 33606, USA
    Mov Disord 24:979-83. 2009
  10. doi request reprint Double-blind trial of levodopa/carbidopa/entacapone versus levodopa/carbidopa in early Parkinson's disease
    Robert A Hauser
    Parkinson s Disease and Movement Disorders Center of Excellence, University of South Florida, 4 Columbia Drive, Suite 410, Tampa, FL 33606, USA
    Mov Disord 24:541-50. 2009

Detail Information

Publications72

  1. doi request reprint IPX066: a novel carbidopa-levodopa extended-release formulation
    Robert A Hauser
    University of South Florida Parkinson s Disease and Movement Disorders Center, NPF Center of Excellence, Byrd Institute, 4001 E Fletcher Ave, 6th Floor, Tampa, FL 33613, USA
    Expert Rev Neurother 12:133-40. 2012
    ....
  2. ncbi request reprint Tozadenant (SYN115) in patients with Parkinson's disease who have motor fluctuations on levodopa: a phase 2b, double-blind, randomised trial
    Robert A Hauser
    University of South Florida Parkinson s Disease and Movement Disorders Center, National Parkinson Foundation Center of Excellence, Tampa, FL, USA Electronic address
    Lancet Neurol 13:767-76. 2014
    ..We aimed to assess the safety and efficacy of tozadenant as an adjunct to levodopa in patients with Parkinson's disease who have motor fluctuations on levodopa...
  3. doi request reprint Extended-release carbidopa-levodopa (IPX066) compared with immediate-release carbidopa-levodopa in patients with Parkinson's disease and motor fluctuations: a phase 3 randomised, double-blind trial
    Robert A Hauser
    University of South Florida, Tampa, FL, USA
    Lancet Neurol 12:346-56. 2013
    ..IPX066 is an oral, extended-release, capsule formulation of carbidopa-levodopa. We aimed to assess this extended-release formulation versus immediate-release carbidopa-levodopa in patients with Parkinson's disease and motor fluctuations...
  4. doi request reprint AbobotulinumtoxinA (Dysport) dosing in cervical dystonia: an exploratory analysis of two large open-label extension studies
    Robert A Hauser
    Parkinson s Disease and Movement Disorders Center, NPF Center of Excellence, Byrd Institute, University of South Florida, 4001 E Fletcher Ave, 6th Floor, Tampa, FL 33613, USA
    J Neural Transm 120:299-307. 2013
    ..Thus, limiting the dose in the sternocleidomastoid may help reduce the incidence of dysphagia...
  5. doi request reprint [123I]FP-CIT (DaTscan) SPECT brain imaging in patients with suspected parkinsonian syndromes
    Robert A Hauser
    Department of Neurology, Parkinson s Disease and Movement Disorders Center, University of South Florida, Tampa, FL 33606, USA
    J Neuroimaging 22:225-30. 2012
    ..To review [(123)I]FP-CIT (Ioflupane I 123, DaTscan) SPECT imaging and its role in clinical practice...
  6. doi request reprint The UPDRS-8: a brief clinical assessment scale for Parkinson's disease
    Robert A Hauser
    Departments of Neurology, Molecular Pharmacology and Physiology, University of South Florida, Tampa, FL, USA
    Int J Neurosci 122:333-7. 2012
    ..Whether it might be useful in clinical trials depends on demonstrating that it is also sensitive to relatively small changes in clinical status...
  7. doi request reprint Levodopa response in early Parkinson's disease
    Robert A Hauser
    Department of Neurology, University of South Florida, Tampa, Florida 33606, USA
    Mov Disord 24:2328-36. 2009
    ..A substantial proportion of subjects with early PD did not experience a robust response to levodopa. An improvement in UPDRSm of approximately 22% best discriminated levodopa treatment from placebo...
  8. doi request reprint Levodopa: past, present, and future
    Robert A Hauser
    Departments of Neurology, Molecular Pharmacology, and Physiology, University of South Florida, Tampa, FL 33606, USA
    Eur Neurol 62:1-8. 2009
    ..Attempts are underway to develop oral and transdermal very long-acting levodopa preparations...
  9. doi request reprint Randomized, double-blind, pilot evaluation of intravenous glutathione in Parkinson's disease
    Robert A Hauser
    Department of Neurology, University of South Florida, Tampa, Florida 33606, USA
    Mov Disord 24:979-83. 2009
    ..54). Glutathione was well tolerated and no safety concerns were identified. Preliminary efficacy data suggest the possibility of a mild symptomatic effect, but this remains to be evaluated in a larger study...
  10. doi request reprint Double-blind trial of levodopa/carbidopa/entacapone versus levodopa/carbidopa in early Parkinson's disease
    Robert A Hauser
    Parkinson s Disease and Movement Disorders Center of Excellence, University of South Florida, 4 Columbia Drive, Suite 410, Tampa, FL 33606, USA
    Mov Disord 24:541-50. 2009
    ..3%) subjects in the LCE group and 16 (7.4%) in the LC group (P = 0.367). Nausea and diarrhea were reported more frequently in the LCE group. LCE provided greater symptomatic benefit than LC and did not increase motor complications...
  11. doi request reprint Study of istradefylline in patients with Parkinson's disease on levodopa with motor fluctuations
    Robert A Hauser
    Department of Neurology, University of South Florida, Tampa, Florida 33606, USA
    Mov Disord 23:2177-85. 2008
    ..We conclude that istradefylline is well tolerated and significantly reduces OFF time as an adjunct to levodopa in PD subjects with motor fluctuations...
  12. ncbi request reprint Early pharmacologic treatment in Parkinson's disease
    Robert A Hauser
    USF Health Movement Disorders Center, 5 Tampa General Circle, Harbourside Medical Tower, Tampa, FL 33606, USA
    Am J Manag Care 16:S100-7. 2010
    ..Physicians should also consider the early use of MAO-B inhibitors in light of their very good tolerability and the recent evidence suggesting long-term disease-modifying effects...
  13. doi request reprint Long-term outcome of early versus delayed rasagiline treatment in early Parkinson's disease
    Robert A Hauser
    Parkinsons s Disease and Movement Disorders Center, University of South Florida, 5 Tampa General Circle, Tampa, FL 33606, USA
    Mov Disord 24:564-73. 2009
    ..This might reflect enduring benefits due to neuroprotection or effects on compensatory mechanisms in early PD...
  14. doi request reprint Future treatments for Parkinson's disease: surfing the PD pipeline
    Robert A Hauser
    Department of Neurology, College of Medicine, University of South Florida, Tampa, Florida 33606, USA
    Int J Neurosci 121:53-62. 2011
    ..Some of these therapies will never be proven efficacious and will not come to market while others may play a key role in the future treatment of PD...
  15. doi request reprint Randomized, double-blind, multicenter evaluation of pramipexole extended release once daily in early Parkinson's disease
    Robert A Hauser
    Department of Neurology, University of South Florida, Tampa, Florida 33606, USA
    Mov Disord 25:2542-9. 2010
    ..Pramipexole ER administered once daily was demonstrated to be efficacious compared with placebo and provided similar efficacy and tolerability as pramipexole IR administered TID...
  16. doi request reprint Long-term, open-label study of once-daily ropinirole prolonged release in early Parkinson's disease
    Robert A Hauser
    Departments of Neurology, Molecular Pharmacology and Physiology, University of South Florida, Tampa, Florida 33606, USA
    Int J Neurosci 121:246-53. 2011
    ..These results support the extended use of ropinirole PR for treatment of PD...
  17. doi request reprint Determination of minimal clinically important change in early and advanced Parkinson's disease
    Robert A Hauser
    Departments of Neurology, Molecular Pharmacology, and Physiology, University of South Florida, Tampa, Florida, USA
    Mov Disord 26:813-8. 2011
    ..9-0.9 hours). We hypothesize that many methodological factors can influence determination of the MCIC, and a range of values is likely to emerge from multiple studies...
  18. doi request reprint Preladenant in patients with Parkinson's disease and motor fluctuations: a phase 2, double-blind, randomised trial
    Robert A Hauser
    University of South Florida, Tampa, FL, USA
    Lancet Neurol 10:221-9. 2011
    ..We aimed to assess the efficacy and safety of preladenant in patients with Parkinson's disease and motor fluctuations who were receiving levodopa and other antiparkinsonian drugs...
  19. ncbi request reprint Long-term efficacy of rasagiline in early Parkinson's disease
    Mark F Lew
    Department of Neurology, Keck University of Southern California School of Medicine, Los Angeles, California 90033, USA
    Int J Neurosci 120:404-8. 2010
    ..Rasagiline was well tolerated, with 11.3% of patients (45/398) withdrawing because of an adverse event. Rasagiline therapy for PD was effective, well tolerated, and safe in this long-term trial...
  20. doi request reprint Treatment of early Parkinson's disease. Part 2
    Tanya Simuni
    Department of Neurology, Northwestern University, Parkinson s Disease and Movement Disorders Center, Chicago, Ill, USA
    Eur Neurol 61:206-15. 2009
    ..Part 2 of the article, presented here, reviews key data relevant to the assessment of potential neuroprotective therapies and the treatment of non-motor symptoms...
  21. doi request reprint Onset of dyskinesia with adjunct ropinirole prolonged-release or additional levodopa in early Parkinson's disease
    Ray L Watts
    Department of Neurology, University of Alabama at Birmingham, Birmingham, Alabama 35294 0017, USA
    Mov Disord 25:858-66. 2010
    ..Ropinirole prolonged-release delayed the onset of dyskinesia with comparable efficacy to increased doses of levodopa in early PD patients not optimally controlled with levodopa...
  22. doi request reprint Long-term safety and efficacy of preladenant in subjects with fluctuating Parkinson's disease
    Stewart A Factor
    Emory University School of Medicine, Department of Neurology, Atlanta, Georgia 30329, USA
    Mov Disord 28:817-20. 2013
    ..Preladenant is a selective adenosine A₂A receptor antagonist under investigation for Parkinson's disease treatment...
  23. doi request reprint Levodopa-induced dyskinesias in Parkinson's disease: etiology, impact on quality of life, and treatments
    Elmyra V Encarnacion
    Department of Neurology, Texas A and M Health Sciences Center, Scott and White National Parkinson Foundation Plummer Movement Disorders Center, Temple, TX, USA
    Eur Neurol 60:57-66. 2008
    ..Several new compounds that may provide an antidyskinetic effect are also under investigation...
  24. ncbi request reprint The controversy concerning plasma homocysteine in Parkinson disease patients treated with levodopa alone or with entacapone: effects of vitamin status
    Theresa A Zesiewicz
    Parkinson s Disease and Movement Disorders Center, University of South Florida, Tampa, 33612, USA
    Clin Neuropharmacol 29:106-11. 2006
    ..In patients with low or low-normal folate levels, levodopa administration is associated with a greater increase in homocysteine and concomitant entacapone administration is associated with a greater reduction in homocysteine...
  25. ncbi request reprint Long-term care of Parkinson's disease. Strategies for managing "wearing off" symptom re-emergence and dyskinesias
    Robert A Hauser
    Parkinson s Disease and Movement Disorders Center, National Parkinson Foundation Center of Excellence, University of South Florida, Tampa, FL, USA
    Geriatrics 61:14-20. 2006
    ..Treatments that reduce motor complications, allowing a higher level of functioning, lessen the burden of care in long-term care settings and increase quality of life for patients and their families...
  26. doi request reprint Early treatment benefits of ropinirole prolonged release in Parkinson's disease patients with motor fluctuations
    Bonnie P Hersh
    Department of Neurology, Harvard Vanguard Medical Associates, Boston, Massachusetts 02215, USA
    Mov Disord 25:927-31. 2010
    ..1; 95%CI, -1.7, -0.5; P = 0.0004), and the cardinal symptoms of PD compared with placebo. These analyses indicate that once-daily, adjunctive ropinirole prolonged release can offer PD symptom control 2 weeks after treatment initiation...
  27. ncbi request reprint Future therapies for Parkinson's disease
    Robert A Hauser
    Department of Neurology, University of South Florida and Tampa General Healthcare, Tampa, FL 33606, USA
    Neurol Clin 22:S149-66. 2004
  28. ncbi request reprint A double-blind placebo-controlled trial of zonisamide (zonegran) in the treatment of essential tremor
    Theresa A Zesiewicz
    Parkinson s Disease and Movement Disorders Center, University of South Florida, Tampa, Florida 33612, USA
    Mov Disord 22:279-82. 2007
    ..ZNS did not provide significant improvements in clinical rating scales at study endpoint compared to placebo and was only modestly well tolerated. ZNS was effective in reducing tremor amplitude as measured by accelerometry...
  29. ncbi request reprint Ten-year follow-up of Parkinson's disease patients randomized to initial therapy with ropinirole or levodopa
    Robert A Hauser
    Parkinson s Disease and Movement Disorders Center, University of South Florida, Tampa, Florida 33606, USA
    Mov Disord 22:2409-17. 2007
    ..Early treatment decisions for individual patients depend largely on the anticipated risk of side effects and long-term complications. Both ropinirole and levodopa are viable treatment options in early PD...
  30. ncbi request reprint Open-label pilot study of levetiracetam (Keppra) for the treatment of levodopa-induced dyskinesias in Parkinson's disease
    Theresa A Zesiewicz
    Parkinson s Disease and Movement Disorders Center, University of South Florida, Tampa, Florida 336112, USA
    Mov Disord 20:1205-9. 2005
    ..There was a 56% dropout rate, mostly due to somnolence. In PD patients who experienced peak-dose dyskinesia for at least 25% of the awake day, LEV significantly improved on time without dyskinesia or with nontroublesome dyskinesia...
  31. ncbi request reprint Open-label pilot study of levetiracetam (Keppra) for the treatment of chorea in Huntington's disease
    Theresa A Zesiewicz
    Parkinson s Disease and Movement Disorders Center and Department of Neurology, University of South Florida, Tampa, Florida 33612, USA
    Mov Disord 21:1998-2001. 2006
    ..6 +/- 26.7 at endpoint; P = 0.24). Somnolence contributed to a 33% drop-out rate, and 3 patients developed Parkinsonism. Results of this open label study suggest that LEV may be efficacious in reducing chorea in HD patients...
  32. ncbi request reprint Levodopa/carbidopa/entacapone (Stalevo)
    Robert A Hauser
    Department of Neurology, University of South Florida and Tampa General Healthcare, Tampa, Florida 33606, USA
    Neurology 62:S64-71. 2004
    ....
  33. doi request reprint Crossover comparison of IPX066 and a standard levodopa formulation in advanced Parkinson's disease
    Robert A Hauser
    Parkinson s Disease and Movement Disorders Center, University of South Florida, Tampa, Florida, USA
    Mov Disord 26:2246-52. 2011
    ..IPX066 provided more sustained plasma levodopa concentrations than immediate-release carbidopa-levodopa. Larger, longer-term, well-controlled studies should be conducted to provide rigorous assessment of the clinical effects of IPX066...
  34. ncbi request reprint Ropinirole therapy for Parkinson's disease
    Rajesh Pahwa
    Department of Neurology, University of Kansas Medical Center, 3599 Rainbow Blvd, Kansas City, KS 66160, USA
    Expert Rev Neurother 4:581-8. 2004
    ..A once-daily formulation of ropinirole is currently in development that has the potential for greater convenience, improved tolerability and greater efficacy...
  35. ncbi request reprint Long-term evaluation of deep brain stimulation of the thalamus
    Rajesh Pahwa
    Department of Neurology, University of Kansas Medical Center, Kansas City, Kansas 66160, USA
    J Neurosurg 104:506-12. 2006
    ..The aim of this study was to evaluate the long-term safety and efficacy of DBS of the ventralis intermedius nucleus (VIM) of the thalamus for PD and ET...
  36. ncbi request reprint A pilot, double-blind, placebo-controlled trial of pregabalin (Lyrica) in the treatment of essential tremor
    Theresa A Zesiewicz
    Parkinson s Disease and Movement Disorders Center, University of South Florida, Tampa, Florida 33612, USA
    Mov Disord 22:1660-3. 2007
    ..PGB provided significant improvements in accelerometry and in action tremor limb scores on the FTM. However, larger studies are needed to further evaluate the potential effect of PGB on ET...
  37. doi request reprint Treatment of early Parkinson's disease. Part 1
    Tanya Simuni
    Department of Neurology, Northwestern University, Parkinson s Disease and Movement Disorders Center, Chicago, Ill 60611, USA
    Eur Neurol 61:193-205. 2009
    ..Safety and tolerability data are also reviewed. Part 2 of the article reviews key findings relevant to the assessment of potential neuroprotective therapies and the treatment of non-motor symptoms...
  38. ncbi request reprint Randomized trial of the adenosine A(2A) receptor antagonist istradefylline in advanced PD
    Robert A Hauser
    Department of Neurology, University of South Florida, and Tampa General Healthcare, 33606, USA
    Neurology 61:297-303. 2003
    ..To evaluate the safety and efficacy of the adenosine A(2A) receptor antagonist istradefylline (KW-6002) in patients with levodopa-treated Parkinson's disease (PD) with both motor fluctuations and peak-dose dyskinesias...
  39. ncbi request reprint Tegaserod (Zelnorm) for the treatment of constipation in Parkinson's disease
    Kelly L Sullivan
    Parkinson s Disease and Movement Disorders Center, NPF Center of Excellence, University of South Florida, Tampa, Florida 33612, USA
    Mov Disord 21:115-6. 2006
    ..There was a trend for improvement in the Subject's Global Assessment (SGA) of satisfaction with bowel habits (NS) and the total SGA (including abdominal discomfort, bothersome constipation, and satisfaction; NS)...
  40. ncbi request reprint Essential tremor. Epidemiology, diagnosis, and treatment
    Kelly L Sullivan
    Department of Neurology, Parkinson s Disease and Movement Disorders Center, Tampa General Hospital Healthcare, University of South Florida, Tampa, Florida 33612, USA
    Neurologist 10:250-8. 2004
    ..Symptoms are typically progressive and potentially disabling, often forcing patients to change jobs or seek early retirement. Proper treatment is contingent on a correct diagnosis, and other possible causes of tremor must be excluded...
  41. doi request reprint A randomized, double-blind, placebo-controlled, delayed start study to assess rasagiline as a disease modifying therapy in Parkinson's disease (the ADAGIO study): rationale, design, and baseline characteristics
    C Warren Olanow
    Department of Neurology, Mount Sinai School of Medicine, New York, New York 10029, USA
    Mov Disord 23:2194-201. 2008
    ..We here describe the rationale for the study and baseline characteristics of the 1,176 patients who have been enrolled into the trial...
  42. ncbi request reprint Clozapine withdrawal symptoms in a Parkinson's disease patient
    Theresa A Zesiewicz
    Department of Neurology, Parkinson s Disease and Movement Disorders Center, University of South Florida and Tampa General Healthcare, Tampa, Florida 33606, USA
    Mov Disord 17:1365-7. 2002
    ..Clozapine should be gradually withdrawn over a period of 1 to 2 weeks when possible, and abruptly discontinued only when necessary...
  43. doi request reprint The independent influence of apathy and depression on cognitive functioning in Parkinson's disease
    London C Butterfield
    Department of Psychology, University of South Florida, 4202 East Fowler Avenue, PCD 4118G, Tampa, FL 33620 7200, USA
    Neuropsychology 24:721-30. 2010
    ....
  44. ncbi request reprint Patient evaluation of a home diary to assess duration and severity of dyskinesia in Parkinson disease
    Robert A Hauser
    Parkinson s Disease and Movement Disorders Center, University of South Florida and Tampa General Healthcare, Tampa, FL 33606, USA
    Clin Neuropharmacol 29:322-30. 2006
    ....
  45. ncbi request reprint Levodopa-induced dyskinesia in Parkinson's disease: epidemiology, etiology, and treatment
    Theresa A Zesiewicz
    Parkinson s Disease and Movement Disorders Center, University of South Florida, Tampa, Florida 33612, USA
    Curr Neurol Neurosci Rep 7:302-10. 2007
    ..Deep brain stimulation of the subthalamic nucleus is now the most commonly used surgical procedure for PD patients, and it is very effective in treating LID...
  46. ncbi request reprint Chorea as a side effect of gabapentin (Neurontin) in a patient with complex regional pain syndrome Type 1
    Theresa A Zesiewicz
    Parkinson s Disease and Movement Disorders Center, NPF Center of Excellence, University of South Florida, Tampa, FL, USA
    Clin Rheumatol 27:389-90. 2008
    ..The chorea lasted for a year and resolved completely within 2 weeks of discontinuing gabapentin...
  47. doi request reprint Randomized clinical trial of fipamezole for dyskinesia in Parkinson disease (FJORD study)
    Peter A LeWitt
    Departments of Neurology, Henry Ford Hospital, Detroit, MI, USA
    Neurology 79:163-9. 2012
    ..The primary study objective was to assess suppression of LID by fipamezole at day 28, as measured by the levodopa-induced dyskinesia scale (LIDS), a modification of the abnormal involuntary movement scale...
  48. ncbi request reprint Quantitative description of loss of clinical benefit following withdrawal of levodopa-carbidopa and bromocriptine in early Parkinson's disease
    Robert A Hauser
    Department of Neurology, University of South Florida and Tampa General Healthcare, Tampa, Florida 33606, USA
    Mov Disord 17:961-8. 2002
    ....
  49. ncbi request reprint Factors associated with the development of motor fluctuations and dyskinesias in Parkinson disease
    Robert A Hauser
    Department of Neurology, University of South Florida, Tampa, FL 33606, USA
    Arch Neurol 63:1756-60. 2006
    ..Motor fluctuations and dyskinesias can cause disability and reduce quality of life for patients with Parkinson disease (PD)...
  50. ncbi request reprint Chorea in a patient with cerebral palsy: treatment with levetiracetam
    Maria V Recio
    Department of Neurology, University of South Florida, Tampa, FL 33612, USA
    Mov Disord 20:762-4. 2005
    ..We report on the case of an adult cerebral palsy patient who developed severe chorea coincident with a febrile illness from a nonstreptococcal infection. The chorea improved markedly with the use of levetiracetam (LEV, Keppra)...
  51. ncbi request reprint Levetiracetam for the treatment of generalized dystonia
    Kelly L Sullivan
    Parkinson s Disease and Movement Disorders Center, University of South Florida, Tampa, FL 33612, USA
    Parkinsonism Relat Disord 11:469-71. 2005
    ..Improvements were noted in blepharospasm, cervical, and truncal dystonia. The patient has been on LEV for a total of 20 weeks, and has experienced sustained improvement of symptoms...
  52. ncbi request reprint Levetiracetam-induced parkinsonism in a Huntington disease patient
    Theresa A Zesiewicz
    Parkinson s Disease and Movement Disorders Center, NPF Centers of Experience, Department of Neurology, University of South Florida Tampa, Florida 33612, USA
    Clin Neuropharmacol 28:188-90. 2005
    ..Symptoms consisted of resting tremor, rigidity, increased dystonia, and gait difficulty. Side effects from levetiracetam resolved completely within 7 days of levetiracetam discontinuation, and chorea returned to baseline...
  53. ncbi request reprint Nonmotor symptoms of Parkinson's disease
    Theresa A Zesiewicz
    Parkinson s Disease and Movement Disorders Center and Department of Neurology, University of South Florida, 12901 Bruce B Downs Blvd, MDC Box 55, Tampa, FL 33612, USA
    Expert Rev Neurother 6:1811-22. 2006
    ..A new screening questionnaire and the revised Unified PD Rating Scale should assist healthcare providers to better identify and evaluate these symptoms. This article reviews the identification and treatment of nonmotor symptoms in PD...
  54. doi request reprint Fentanyl-induced bradykinesia and rigidity after deep brain stimulation in a patient with Parkinson disease
    Theresa A Zesiewicz
    Parkinson s Disease and Movement Disorders Center, Department of Neurology, University of South Florida, Tampa, 33612, USA
    Clin Neuropharmacol 32:48-50. 2009
    ..The severe bradykinesia and rigidity persisted despite reactivation of the deep brain stimulator and immediate reinstitution of Parkinson disease medications, but resolved completely several hours after discontinuation of fentanyl...
  55. ncbi request reprint Zydis selegiline reduces off time in Parkinson's disease patients with motor fluctuations: a 3-month, randomized, placebo-controlled study
    Cheryl H Waters
    Department of Neurology, Columbia University, New York, New York 10032, USA
    Mov Disord 19:426-32. 2004
    ..Adverse events were consistent with known effects of levodopa therapy. Zydis selegiline safely reduces daily off time when used as adjunctive therapy with levodopa in patients with PD...
  56. ncbi request reprint Duodenal levodopa infusion for the treatment of Parkinson's disease
    Johan Samanta
    University of Arizona, Banner Good Samaritan Medical Center, Department of Neurology, College of Medicine, Phoenix, AZ 85258 USA
    Expert Opin Pharmacother 8:657-64. 2007
    ..This article reviews the published data describing the efficacy and safety of duodenal levodopa, and discusses its current and potential role in meeting the needs of PD patients...
  57. ncbi request reprint Pregabalin (Lyrica) in the treatment of essential tremor
    Theresa A Zesiewicz
    Parkinson s Disease and Movement Disorders Center, Department of Neurology, Neuroscience Program, University of South Florida, Tampa, Florida 33612, USA
    Mov Disord 22:139-41. 2007
    ..Both patients also reported moderate reduction in tremor on the Clinical Global Impression Scale, and Fahn-Tolosa-Marin Part I scores were markedly improved...
  58. ncbi request reprint Substantial improvement in a Meige's syndrome patient with levetiracetam treatment
    Theresa A Zesiewicz
    Parkinson s Disease and Movement Disorders Center, University of South Florida, Tampa, Florida, USA
    Mov Disord 19:1518-21. 2004
    ..This report and data from an animal model of paroxysmal dystonia suggest that LEV might be helpful in the treatment of dystonia...
  59. ncbi request reprint Advances in the pharmacologic management of early Parkinson disease
    Robert A Hauser
    Department of Neurology, Parkinson s Disease and Movement Disorders Center, University of South Florida and Tampa General Healthcare, Tampa, Florida 33606, USA
    Neurologist 13:126-32. 2007
    ..However, the disease continues to progress, and the long-term use of levodopa is associated with the development of motor fluctuations and dyskinesias...
  60. doi request reprint New considerations in the medical management of early Parkinson's disease: impact of recent clinical trials on treatment strategy
    Robert A Hauser
    University of South Florida, Department of Neurology, Tampa, FL 33606, USA
    Parkinsonism Relat Disord 15:S17-21. 2009
    ..The current approach to treatment of early PD depends in part on individual patient factors including age, severity of motor signs, presence of cognitive dysfunction, and other co-morbidities...
  61. ncbi request reprint Clinical trials aimed at detecting neuroprotection in Parkinson's disease
    Robert A Hauser
    Department of Neurology, University of South Florida, Tampa General Healthcare, Tampa, Florida, USA
    Neurology 66:S58-68. 2006
    ..Better methods of assessing putative neuroprotection in PD are needed...
  62. doi request reprint Levetiracetam for stiff-person syndrome: report of 2 patients
    W Reed Shimberg
    Parkinson s Disease and Movement Disorders Center, NPF Center of Excellence, Tampa, Florida, USA
    Clin Neuropharmacol 31:301-2. 2008
    ..We report 2 patients with stiff-person syndrome whose spasms were greatly relieved by levetiracetam (Keppra)...
  63. ncbi request reprint Randomized trial of the triple monoamine reuptake inhibitor NS 2330 (tesofensine) in early Parkinson's disease
    Robert A Hauser
    Department of Neurology, University of South Florida and Tampa General Healthcare, NPF Center of Excellence, Tampa, Florida 33606, USA
    Mov Disord 22:359-65. 2007
    ....
  64. ncbi request reprint Translocation breakpoint in two unrelated Tourette syndrome cases, within a region previously linked to the disorder
    Fiona C Crawford
    Department of Psychiatry, University of South Florida, 3515 E Fletcher Avenue, Tampa, FL 33613, USA
    Hum Genet 113:154-61. 2003
    ....
  65. ncbi request reprint Parkinson's disease home diary: further validation and implications for clinical trials
    Robert A Hauser
    Department of Neurology, University of South Florida, Tampa, Florida, USA
    Mov Disord 19:1409-13. 2004
    ..Good on time (ONG = on time without dyskinesia or with nontroublesome dyskinesia) most strongly correlated with patients' perceived duration of a good response through the day and is an important outcome variable...
  66. ncbi request reprint Topiramate-induced psychosis in patients with essential tremor: report of 2 cases
    Theresa A Zesiewicz
    Parkinson s Disease and Movement Disorders Center, University of South Florida, Tampa, 33612, USA
    Clin Neuropharmacol 29:168-9. 2006
    ..All adverse symptoms resolved several days after topiramate was discontinued...
  67. ncbi request reprint Sleep attacks and dopamine agonists for Parkinson's disease: what is currently known?
    Theresa A Zesiewicz
    Parkinson s Disease and Movement Disorders Center and Department of Neurology, University of South Florida, Tampa General Healthcare, Tampa, Florida 33606, USA
    CNS Drugs 17:593-600. 2003
    ..Patients with Parkinson's disease and caregivers should be informed about the risk of sleepiness and sleep attacks associated with dopaminergic medications and the potential implications for driving safety...
  68. ncbi request reprint Adenosine A2A receptor antagonists for Parkinson's disease: rationale, therapeutic potential and clinical experience
    Robert A Hauser
    Department of Neurology, University of South Florida and Tampa General Healthcare, Tampa, Florida 33606, USA
    Drugs Aging 22:471-82. 2005
    ..Additional studies are necessary to evaluate the benefit of istradefylline as monotherapy in early disease, its effect on the development of dyskinesia, and its effect on disease progression...
  69. ncbi request reprint Deep brain stimulation of the internal segment of the globus pallidus in delayed runaway dyskinesia
    John Graff-Radford
    Department of Neurology, University of Florida Movement Disorders Center, University of Florida, Gainesville, FL, USA
    Arch Neurol 63:1181-4. 2006
    ....
  70. ncbi request reprint Use of nutritional supplements in Parkinson's disease patients
    Summer C Wolfrath
    Parkinson s Disease and Movement Disorders Center, NPF Center of Excellence, and Department of Neurology, College of Medicine, University of South Florida, Tampa, Florida, USA
    Mov Disord 21:1098-101. 2006
    ..Greater awareness of nutritional supplement use in PD patients is warranted to avoid potentially harmful effects and drug interactions...
  71. ncbi request reprint Management of essential tremor
    Theresa A Zesiewicz
    Parkinson s Disease and Movement Disorders Center and Department of Neurology, University of South Florida, Harborside Medical Tower, 4 Columbia Drive, Suite 410, Tampa, FL 33606, USA
    Curr Neurol Neurosci Rep 2:324-30. 2002
    ..In patients with medically refractory tremor, alternative therapies, including surgery or injections of botulinum toxin, may be considered...
  72. ncbi request reprint Depression in Parkinson's disease
    Theresa A Zesiewicz
    Parkinson s Disease and Movement Disorders Center, University of South Florida College of Medicine, 4 Columbia Drive, Suite 410, Tampa, FL 33606, USA
    Curr Psychiatry Rep 4:69-73. 2002
    ..This information may help guide clinical treatment and define the need for further studies...